Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Acute oral digoxin in healthy adults hastens fatigue and increases plasma K<sup>+</sup> during intense exercise, despite preserved skeletal muscle Na<sup>+</sup>,K<sup>+</sup>-ATPase.

The Journal of physiology·2024
Same author

Digoxin and exercise effects on skeletal muscle Na<sup>+</sup>,K<sup>+</sup>-ATPase isoform gene expression in healthy humans.

Experimental physiology·2024
Same author

Oral digoxin effects on exercise performance, K<sup>+</sup> regulation and skeletal muscle Na<sup>+</sup> ,K<sup>+</sup> -ATPase in healthy humans.

The Journal of physiology·2022
Same author

Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure.

ESC heart failure·2021
Same author

Insulin-like growth factor-1 directly affects cardiac cellular remodelling <i>via</i> distinct pathways.

International journal of cardiology. Heart & vasculature·2021
Same author

Kidney age - chronological age difference (KCD) score provides an age-adapted measure of kidney function.

BMC nephrology·2021
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 24, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

心不全は,心不全によるものです.

Henry Krum1, William T Abraham

  • 1Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

Lancet (London, England)
|March 17, 2009
PubMed
まとめ
この要約は機械生成です。

心不全の管理は進歩しているが,依然として公衆衛生上の重大な問題である. 現在の治療は,神経ホルモン系を遮断し,高度な段階のデバイスを使用して,液体バランスを管理することに焦点を当てています.

さらに関連する動画

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

関連する実験動画

Last Updated: Jun 24, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

科学分野:

  • 心臓病学 心臓病学
  • 公衆衛生は公衆衛生である.
  • 薬理学 薬理学とは

背景:

  • 心不全 (HF) は,治療の進歩にもかかわらず,高い罹患率,不良の臨床結果,およびかなりの医療費によって特徴づけられる主要な公衆衛生問題として持続しています.
  • HFの確立されたリスク要因はよく理解されており,予防戦略が疾患の負担を大幅に軽減することを示唆しています.
  • 慢性性静脈性HFの現在の管理は,有害な心臓の改造を軽減し,症状を緩和し,生存率を改善するために,神経ホルモンブロック (レニン-アンジオテンシン-アルドステロンおよび交感性神経系) を含む.

研究 の 目的:

  • 薬理学的およびデバイスベースの治療法を含む,心不全の現在の管理戦略をレビューする.
  • 急性HFおよびHFを保存されたエジェクション分数で治療する証拠の限界を強調する.
  • 新規の診断ツール,治療目標,再生医療アプローチを含む,パーソナライズされたHF管理のための新興戦略を探求する.

主な方法:

  • 心不全の既定および新興治療法のレビュー.
  • 慢性シストリック心不全,急性心不全,噴出分子が保存された心不全の管理のための現在のガイドラインの分析.
  • 再生医療やパーソナライズド・トリートメントのアプローチを含む,新しい治療方法の探求.

主要な成果:

  • 慢性性シストリックHFの標準的な治療法は,神経ホルモン抗薬と利尿薬,心臓再同期および進んだ症例の除細動器の埋め込みなどのデバイス療法を含む.
  • 急性HFおよび保存されたエエジェクション分子を含むHFの治療法を支持する臨床的証拠は依然として限られています.
  • 新興戦略は,パーソナライズされた治療,高度な診断,新薬学的標的,細胞ベースの治療法や遺伝子ベースの治療法などの再生療法に焦点を当てています.

結論:

  • 進歩にもかかわらず,心不全は多面的な管理戦略を必要とする重要な公衆衛生上の課題であり続けています.
  • 現在の証拠のギャップは,特に急性HFと保存された射出分数を持つHFについて,さらなる研究を必要とします.
  • 心不全の管理における将来の方向性は,パーソナライズされた医療,革新的な診断,心臓修復のための再生アプローチを含む.